Caliper Life Sciences has announced expanded sales of its LabChip 3000 drug discovery system with top tier customers including AstraZeneca, Novartis and Vertex Pharmaceuticals
The LabChip 3000 improves drug discovery and development by employing microfluidic technology, which enables researchers to generate screening and profiling data that reduces artifacts, enhances understanding of biological interactions and ultimately helps scientists better predict which compounds will be successful drug candidates.
The sensitivity and reproducibility of microfluidic experimentation reduces false positives and false negatives, and empowers researchers with analytical quality data that allows them to detect subtle interactions between drug candidates and therapeutic targets.
In addition, the LabChip 3000 simplifies drug discovery by enabling a broad range of enzymatic and cellular assays on a single integrated platform.
Currently 12 of the top 15 pharmaceutical companies actively use Caliper systems as key tools in their discovery efforts.
"Our customers demand products that accelerate drug discovery and development by providing the most accurate and reliable experimentation results".
"Increasingly, the pharmaceutical and biotech industries are recognizing the LabChip 3000's ability to deliver those results," said Kevin Hrusovsky, CEO, Caliper Life Sciences.
"Sales of LabChip systems have grown rapidly over the past couple of years, to the point that this product line drove our strong organic growth in the first quarter of this year".
"Continued wins with existing and new customers illustrate the positive industry traction we are seeing in our microfluidics business."
